FWM
ALXN

Focused Wealth Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Focused Wealth Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-5,600
Closed -$20K – 739
2018
Q2 		$20K Buy
+5,600
New +$654K 0.01% 363

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Focused Wealth Management's ALXN Position: Q4 2016 in Review

Focused Wealth Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2016, closing a stake of 40 shares — an estimated $5K sold.

Focused Wealth Management first reported a position in ALXN in Q3 2013 and held it in 13 quarters. The position peaked at $35K in Q4 2013. 548 funds tracked by Wall St. Rank hold ALXN as of Q4 2016.

  • Focused Wealth Management reported no remaining Alexion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Focused Wealth Management sold 40 Alexion Pharmaceuticals shares in Q4 2016, an estimated $5K.
  • Focused Wealth Management first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 13 quarters.
  • Focused Wealth Management's Alexion Pharmaceuticals position peaked at $35K in Q4 2013.
  • 548 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2016.

Based on Focused Wealth Management's 13F filing for Q4 2016, filed 14 Feb 2017.